GL Pharm Tech: 투자판단관련주요경영사항(임상시험계획승인신청등결정) (W2505 경구제 제 3상 임상시험계획(IND) 승인)

비뇨기 질환 치료제(W2505) 임상 3상 계획 승인

Key figures: 임상 3상 승인

An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).

• 09.21 ★★ [Correction] Execution of Supply Contract